Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Is discussion of dengue vaccination for the 2016 Olympics necessary?

Scott Halstead and Maira Aguiar1 ask if visitors to the 2016 Olympic Games in Rio de Janeiro might be tempted to obtain dengue vaccination (Dengvaxia) through the private market in Brazil. They state that Dengvaxia might not protect flavivirus-naive individuals, and that vaccination in children aged 2–5 years could increase their risk of hospital admission for breakthrough dengue infection. First, in Brazil, Dengvaxia is indicated for prevention of dengue disease caused by the four dengue serotypes in individuals aged 9–45 years living in endemic areas.